Analysts Set Expectations for Eli Lilly and Co.’s FY2018 Earnings (LLY)
Eli Lilly and Co. (NYSE:LLY) – Analysts at Leerink Swann lifted their FY2018 EPS estimates for Eli Lilly and in a research note issued to investors on Thursday. Leerink Swann analyst S. Fernandez now anticipates that the firm will post earnings per share of $4.35 for the year, up from their previous forecast of $4.21. Leerink Swann currently has a “Buy” rating and a $103.00 price target on the stock. Leerink Swann also issued estimates for Eli Lilly and’s FY2019 earnings at $5.05 EPS and FY2020 earnings at $5.55 EPS.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.86. The firm had revenue of $5.40 billion for the quarter, compared to analyst estimates of $5.14 billion. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. Eli Lilly and’s revenue was up 8.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.90 earnings per share.
A number of other analysts have also recently weighed in on the company. Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Wednesday, October 5th. BMO Capital Markets reiterated a “buy” rating and issued a $94.00 price target on shares of Eli Lilly and in a research report on Monday, October 3rd. Goldman Sachs Group Inc. upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and upped their price target for the company from $89.00 to $95.00 in a research report on Tuesday, September 27th. Deutsche Bank AG reiterated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, September 20th. Finally, Jefferies Group reiterated a “buy” rating and issued a $105.00 price target on shares of Eli Lilly and in a research report on Wednesday, September 14th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Eli Lilly and presently has a consensus rating of “Buy” and a consensus target price of $97.06.
Eli Lilly and (NYSE:LLY) traded down 1.59% on Monday, reaching $80.51. The company had a trading volume of 3,622,794 shares. Eli Lilly and has a 12 month low of $67.88 and a 12 month high of $88.16. The company has a market capitalization of $85.16 billion, a price-to-earnings ratio of 34.70 and a beta of 0.17. The company’s 50 day moving average price is $79.63 and its 200-day moving average price is $77.69.
A number of large investors have recently added to or reduced their stakes in the stock. Iowa State Bank bought a new stake in Eli Lilly and during the second quarter worth approximately $104,000. PineBridge Investments L.P. increased its stake in Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock worth $108,000 after buying an additional 920 shares in the last quarter. Cribstone Capital Management LLC bought a new stake in Eli Lilly and during the second quarter worth approximately $117,000. Coconut Grove Bank increased its stake in Eli Lilly and by 3.3% in the second quarter. Coconut Grove Bank now owns 1,550 shares of the company’s stock worth $122,000 after buying an additional 50 shares in the last quarter. Finally, Physicians Financial Services Inc. increased its stake in Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock worth $129,000 after buying an additional 165 shares in the last quarter. Institutional investors and hedge funds own 74.96% of the company’s stock.
In related news, insider Donald A. Zakrowski sold 1,213 shares of the company’s stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $83.16, for a total value of $100,873.08. Following the completion of the sale, the insider now owns 1,300 shares in the company, valued at $108,108. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 240,000 shares of the company’s stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $82.87, for a total value of $19,888,800.00. Following the completion of the sale, the insider now owns 126,020,570 shares of the company’s stock, valued at approximately $10,443,324,635.90. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.